Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHS National Pharmaceuticals Transition 2019_1
Offer reference number: CM/PHG/17/5547
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 34 months
Potential periods of call-offs under the framework agreement:
LSNE: 01/10/2019 to 30/04/2020 (7 months)
CESW: 01/10/2019 to 30/09/2020 (12 months)
NWLN: 01/10/2019 to 28/02/2021 (17 months)
Awarded product list bortezomib, arsenic, darunavir, atazanavir, ritonavir, miglustat, gefitinib, carglumic acid, clofaribine, ganciclovir, aprepitant, dexmedetomidine, solifenacin, atomoxetine, atovaquone, metaraminol and olopatadine
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Please see list of awarded suppliers (including SME status) at t | - | £28,656,720 | - |